BioCentury
ARTICLE | Company News

Universite catholique de Louvain, arGEN-X deal

March 23, 2015 7:00 AM UTC

arGEN-X exercised an exclusive option to license worldwide rights to a preclinical mAb against leucine-rich repeat containing 32 ( LRRC32; GARP) from the de Duve Institute at the university. arGEN-X...